Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)

P Chue - Current pharmaceutical design, 2013 - ingentaconnect.com
Primary negative symptoms (affective flattening or blunting, alogia, avolition) are prominent
in approximately 20% of individuals suffering from schizophrenia. These symptoms are …
被引用次数：41 相关文章

[引用][C] Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the Glycine Transporter 1 (GlyT1)

P CHUE - Current pharmaceutical design (Print), 2013 - pascal-francis.inist.fr
Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on
the Glycine Transporter 1 (GlyT1) CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)

P Chue - Current pharmaceutical design, 2013 - pubmed.ncbi.nlm.nih.gov
Primary negative symptoms (affective flattening or blunting, alogia, avolition) are prominent
in approximately 20% of individuals suffering from schizophrenia. These symptoms are …

Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).

P Chue - Current Pharmaceutical Design, 2013 - europepmc.org
Primary negative symptoms (affective flattening or blunting, alogia, avolition) are prominent
in approximately 20% of individuals suffering from schizophrenia. These symptoms are …

Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1)

P Chue - Current Pharmaceutical Design, 2013 - hero.epa.gov
Primary negative symptoms (affective flattening or blunting, alogia, avolition) are prominent
in approximately 20% of individuals suffering from schizophrenia. These symptoms are …

[引用][C] Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the Glycine Transporter 1 (GlyT1)

P Chue - Current Pharmaceutical Design, 2012 - cir.nii.ac.jp
Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the
Glycine Transporter 1 (GlyT1) | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

[引用][C] Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the Glycine Transporter 1 (GlyT1)

P Chue - Current Pharmaceutical Design, 2012 - cir.nii.ac.jp
Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the
Glycine Transporter 1 (GlyT1) | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

[引用][C] Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the Glycine Transporter 1 (GlyT1)

P CHUE - Current pharmaceutical design, 2013 - Bentham